Boris Reva

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Threading with chemostructural restrictions method for predicting fold and functionally significant residues: application to dipeptidylpeptidase IV (DPP-IV)
    Boris Reva
    Novartis Institute for Biomedical Research, Summit, New Jersey, USA
    Proteins 47:180-93. 2002
  2. pmc Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma
    Javier Cotignola
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med Genet 8:10. 2007
  3. pmc Determinants of protein function revealed by combinatorial entropy optimization
    Boris Reva
    Computational Biology Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Genome Biol 8:R232. 2007
  4. pmc The molecular diversity of Luminal A breast tumors
    Giovanni Ciriello
    Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Breast Cancer Res Treat 141:409-20. 2013
  5. doi Strand-specific in vivo screen of cancer-associated miRNAs unveils a role for miR-21(∗) in SCC progression
    Yejing Ge
    Howard Hughes Medical Institute and Laboratory of Mammalian Cell Biology and Development, Rockefeller University, New York, New York 10065, USA
    Nat Cell Biol 18:111-21. 2016
  6. pmc MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking
    Maria E Arcila
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 21:1935-43. 2015
  7. pmc Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma
    Justin Rendleman
    NYU School of Medicine, New York University, New York, New York, United States of America
    PLoS ONE 9:e101685. 2014
  8. pmc Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas
    Daniel Schramek
    Howard Hughes Medical Institute, Laboratory of Mammalian Cell Biology and Development, The Rockefeller University, New York, NY 10065, USA
    Science 343:309-13. 2014
  9. pmc Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network
    A Ari Hakimi
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 19:3259-67. 2013
  10. pmc Necdin, a p53 target gene, regulates the quiescence and response to genotoxic stress of hematopoietic stem/progenitor cells
    Takashi Asai
    Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 120:1601-12. 2012

Collaborators

Detail Information

Publications12

  1. ncbi Threading with chemostructural restrictions method for predicting fold and functionally significant residues: application to dipeptidylpeptidase IV (DPP-IV)
    Boris Reva
    Novartis Institute for Biomedical Research, Summit, New Jersey, USA
    Proteins 47:180-93. 2002
    ..Cell 1998;94:161-170) and use this structure for modeling the interaction of DPP-IV with inhibitor...
  2. pmc Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma
    Javier Cotignola
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med Genet 8:10. 2007
    ..Some polymorphisms are known to influence gene expression, protein activity, stability, and interactions, and they were shown to be associated with certain tumor phenotypes and cancer risk...
  3. pmc Determinants of protein function revealed by combinatorial entropy optimization
    Boris Reva
    Computational Biology Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Genome Biol 8:R232. 2007
    ..Such predicted functional determinants are useful for interpreting the functional consequences of mutations in natural evolution and disease...
  4. pmc The molecular diversity of Luminal A breast tumors
    Giovanni Ciriello
    Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Breast Cancer Res Treat 141:409-20. 2013
    ..Our work provides for a further molecular stratification of Luminal A breast tumors, with potential direct clinical implications. ..
  5. doi Strand-specific in vivo screen of cancer-associated miRNAs unveils a role for miR-21(∗) in SCC progression
    Yejing Ge
    Howard Hughes Medical Institute and Laboratory of Mammalian Cell Biology and Development, Rockefeller University, New York, New York 10065, USA
    Nat Cell Biol 18:111-21. 2016
    ..Through in vivo physiological miR screens, our findings add an interesting twist to an increasingly important oncomiR locus. ..
  6. pmc MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking
    Maria E Arcila
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 21:1935-43. 2015
    ..Somatic mutations in MEK1, located downstream of BRAF, are rare and remain poorly defined as a distinct molecular subset...
  7. pmc Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma
    Justin Rendleman
    NYU School of Medicine, New York University, New York, New York, United States of America
    PLoS ONE 9:e101685. 2014
    ..While the findings generated here warrant independent validation, the results of our large study suggest that ATM may be a novel locus associated with the risk of multiple subtypes of NHL...
  8. pmc Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas
    Daniel Schramek
    Howard Hughes Medical Institute, Laboratory of Mammalian Cell Biology and Development, The Rockefeller University, New York, NY 10065, USA
    Science 343:309-13. 2014
    ..Myosin IIa is diminished in human SCCs with poor survival, which suggests that in vivo RNAi technology might be useful for identifying potent but low-penetrance tumor suppressors. ..
  9. pmc Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network
    A Ari Hakimi
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 19:3259-67. 2013
    ..To investigate the impact of newly identified chromosome 3p21 epigenetic tumor suppressors PBRM1, SETD2, and BAP1 on cancer-specific survival (CSS) of 609 patients with clear cell renal cell carcinoma (ccRCC) from 2 distinct cohorts...
  10. pmc Necdin, a p53 target gene, regulates the quiescence and response to genotoxic stress of hematopoietic stem/progenitor cells
    Takashi Asai
    Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 120:1601-12. 2012
    ..We conclude that necdin functions as a molecular switch in adult hematopoiesis, acting in a p53-like manner to promote HSC quiescence in the steady state, but suppressing p53-dependent apoptosis in response to genotoxic stress...
  11. pmc The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data
    Ethan Cerami
    Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Discov 2:401-4. 2012
    ....
  12. pmc Predicting the functional impact of protein mutations: application to cancer genomics
    Boris Reva
    Computational Biology Center, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Nucleic Acids Res 39:e118. 2011
    ..In addition, we estimate that at least 5% of cancer-relevant mutations involve switch of function, rather than simply loss or gain of function...